GLP-1s: The problem isn’t the medication itself. It’s that we’ve built an elegant on-ramp for

GLP-1s: The problem isn’t the medication itself. It’s that we’ve built an elegant on-ramp for GLP-1s—and almost no off-ramp at all.

Archive

This is a stored Optics snapshot.It preserves the source map and wording analysis from 10/21/2026, 1:16:59 AM.

30-SECOND READ

What happenedGLP-1s: The problem isn’t the medication itself. It’s that we’ve built an elegant on-ramp for GLP-1s—and almost no off-ramp at all.

What changedThe headlines are mostly aligned. The differences are small wording choices, not a major framing split.

ConfidenceLow. The source map includes different article formats, so wording may reflect format as well as framing.

Archive healthDeveloping · related angle

WORDING GAP

0WORDING GAP

1 sources · 1 bias buckets · Low confidence

Developing comparison. The source map includes different article formats, so wording may reflect format as well as framing.

SOURCE MAP TIMELINE

Oct 20, 10:00 PM: Instapundit joined the source map.

Now: score hidden until the source match is cleaner. Story health is developing · related angle.

Flagged: article formats differ, so wording may reflect format as well as framing.

ARCHIVED SOURCES

Right ·Opinion

GLP-1s: The problem isn’t the medication itself. It’s that we’ve built an elegant on-ramp for GLP-1s—and almost no off-ramp at all.